Tick-Derived Polypeptides for Brain Inflammation After Hemorrhage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for brain inflammation, particularly following intracerebral hemorrhage, are limited and often exacerbate the condition, leading to severe disability and poor clinical outcomes without effectively addressing neuroinflammation.
Innovation Solution
A protein or polypeptide with at least 75% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, derived from Ixodes ricinus salivary gland, is administered to prevent or treat brain inflammation, reducing neuroinflammation without increasing hemorrhage volume or edema.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for brain inflammation are administered, then neuroinflammation is targeted, but hemorrhage volume increases and clinical outcomes worsen
Solution Approach 1:
The patent uses a specific polypeptide (Ir-CPI or its variants) as an intermediary substance that selectively modulates the inflammatory response without affecting hemorrhage expansion. This polypeptide acts as a mediator between the hemorrhage event and the inflammatory response, allowing treatment of neuroinflammation while preventing harmful hemorrhage volume increase.
Solution Approach 2:
The patent applies parameter changes by modifying the polypeptide sequence (creating variants with at least 75% identity to SEQ ID NO: 1) to optimize its anti-inflammatory activity while maintaining safety profile. The specific amino acid sequence parameters are tuned to achieve selective inhibition of neuroinflammation without promoting hemorrhage expansion.
2Object-affected harmful factors
If anti-inflammatory agents are used to treat neuroinflammation, then inflammatory response is reduced, but hemorrhage aggravation occurs
Solution Approach 1:
The patent inverts the conventional approach by using a polypeptide derived from tick salivary glands that naturally possesses anti-inflammatory properties without the side effect of hemorrhage aggravation. Instead of using conventional anti-inflammatory drugs that cause hemorrhage expansion, the invention uses a biologically derived polypeptide that works in the opposite manner - reducing inflammation while maintaining hemorrhage stability.
Solution Approach 2:
The patent converts a potentially harmful substance (tick salivary gland polypeptide that could theoretically affect coagulation) into a beneficial treatment by demonstrating its selective anti-inflammatory action. The polypeptide's natural biological activity is harnessed to treat neuroinflammation while avoiding the harmful effect of hemorrhage aggravation that plagues conventional anti-inflammatory agents.
3Productivity
If current stroke treatments are administered, then supportive care is provided, but functional independence remains low at 6 months
Solution Approach 1:
The patent applies preliminary action by administering the polypeptide early after intracerebral hemorrhage to prevent the development of severe neuroinflammation. By acting preemptively during the critical early period (before 72 hours), the treatment prevents the inflammatory cascade that would otherwise lead to poor long-term outcomes, thereby improving functional independence more quickly than conventional supportive care alone.
Data Source
Figure 1A~1D
Figure 2A~2C
Figure 3
AI summary
The present invention relates to proteins and polypeptides for their use for preventing and/or treating brain inflammation and diseases or conditions associated with brain inflammation, and methods for preventing and/or treating brain inflammation and diseases or conditions associated with brain inflammation.